TransMedics Group Inc vs WD 40 Company — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while WD 40 Company trades at $237.72 (market cap $3.22B). The key difference: WD 40 Company is the larger of the two by market cap, and WD 40 Company pays a 1.7% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WDFC | |
|---|---|---|
Market Cap | $2.54B | $3.22B |
Sector | Technology | Technology |
52-Week High | $150.42 | $264.91 |
52-Week Low | $61.99 | $187.52 |
Enterprise Value | $2.94B | $3.27B |
Dividend Yield | — | 1.7% |
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
WDFC trades at $239.59, down 2.92% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 earnings of $2.33 per share, beating estimates, and maintains solid profitability with a 13.22% net income margin. Recent news highlights its brand strength and efficient operations, though some analysts see limited upside.
The outlook is balanced: earnings beats and a strong brand provide support, but high valuation multiples (P/E 36.44) and mixed analyst sentiment (71.42% hold rating) suggest cautious optimism. Key risks include margin pressure from input costs and competitive challenges, requiring careful monitoring of future earnings consistency.
Trailing returns across standard periods
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →